Ascendis Pharma AS (ASND) Actualités

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis Pharma Reports Third Quarter 2024 Financial Results

– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

-  Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]